Different manufacturers of syringes: A new source of variability in blood gas, acid-base balance and related laboratory test?

被引：26

作者：

Lima-Oliveira, Gabriel ^{[1
,2
,3
,4
]}

Lippi, Giuseppe ^{[5
]}

Salvagno, Gian Luca ^{[1
]}

Montagnana, Martina ^{[1
]}

Picheth, Geraldo ^{[2
]}

Guidi, Gian Cesare ^{[1
,2
]}

机构：

[1] Univ Verona, Dept Life & Reprod Sci, Lab Clin Biochem, I-37100 Verona, Italy

[2] Univ Fed Parana, Dept Med Pathol, Postgrad Program Pharmaceut Sci, BR-80060000 Curitiba, Parana, Brazil

[3] MERCOSUL Sect Comm Clin Anal & Vitro Diagnost CSM, Rio De Janeiro, Brazil

[4] Brazilian Soc Clin Anal Sao Paulo State, Sao Paulo, Brazil

[5] Azienda Osped Univ Parma, UO Diagnost Ematochim, Parma, Italy

来源：

CLINICAL BIOCHEMISTRY | 2012年 / 45卷 / 09期

关键词：

Blood specimen collection; Blood gas; Heparin; Intensive care unit; ISO; 15189; Preanalytical variability; Syringe; IONIZED CALCIUM; BIOLOGICAL VARIATION; QUALITY IMPROVEMENT; OXYGEN-TENSION; ARTERIAL-BLOOD; HEPARIN;

D O I：

10.1016/j.clinbiochem.2012.03.007

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objective: Evaluate whether four different brands/types of heparin coated syringes can represent a source of variability in blood gas analysis (BGA). Design and methods: Blood was collected from one hundred volunteers into different syringes: Syringe I (lithium heparin and calcium balanced); Syringe II: in-house prepared (sodium heparin); Syringe III: (spray-dried calcium-balanced lithium heparin); Syringe IV (lyophilized electrolyte-balanced lithium heparin). Results: Significant differences were as follows: a) Syringe I vs II: pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), base excess (BE), total hemoglobin (tHb), sodium (Na+), potassium (K+), calcium (Ca2+), glucose (Glu), lactate (Lac), O-2 Hb and p 50; b) Syringe I vs III: pH, pO(2), cHCO(3)(-), ctCO(2), BE, Na+, Glu, Lac and p 50; c) Syringe I vs IV: pH, pO(2), sO(2), pCO(2)(t), BE, Na+, K+, Ca2+, Glu, Lac and O-2 Hb; d) Syringe II vs III: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), ctO(2), tHb, Na+, K+, Ca2+, Lac, and p 50; e) Syringe II vs IV: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), BE, tHb, Na+, K+, Ca2+, Lac, O-2 Hb and p 50; f) Syringe III vs IV: pH, pO(2), sO(2), cHCO(3)(-), ctCO(2), ctO(2), BE, Na+, K+, Ca2+, O-2 Hb and p 50. Conclusion: The different manufacturers of syringes can represent new source of variability on BGA. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：683 / 687

页数：5

共 41 条

[21] Risk management in the preanalytical phase of laboratory testing [J].